In recent years, several novel therapeutic classes for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including antibody-drug conjugates, CAR T, and most recently, bispecific T-cell engaging antibodies, have emerged. During this activity, a panel of clinical experts will present the latest data on these therapeutic advances. They will also discuss the integration of these treatments in clinical practice while a patient with R/R DLBCL shares key aspects of their therapeutic journey.
Upon completion of this activity, participants should be better able to:
Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY
Assistant Attending, Lymphoma Service and Cellular Therapy Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor, Medicine
Weill Cornell Medical College
New York, NY
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia
John Theurer Cancer Center
Associate Professor, Hackensack Meridian School of Medicine
Hackensack, NJ
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
